Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.52 |
| ▸ | PTPRC | P08575 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | CETP | P11597 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6397780 | 0.86 | PTPN1 (0.60) | PTPN1PTPRCALDH1A1TSHRMAPK1 | |
| SCHEMBL19598833 | 0.84 | PTPN1 (0.52) | PTPN1PTPRCALDH1A1CETPTSHR | |
| SCHEMBL29009442 | 0.82 | MMP8 (0.56) | PTPN1PTPRCALDH1A1KMT2ALMNA | |
| SCHEMBL2659137 | 0.81 | PTPN1 (0.55) | PTPN1PTPRCALDH1A1CETPTSHR | |
| SCHEMBL7685660 | 0.80 | CETP (0.49) | PTPN1PTPRCALDH1A1CETPTSHR | |
| SCHEMBL3047519 | 0.79 | ALDH1A1 (0.47) | PTPN1PTPRCALDH1A1CETPTSHR | |
| SCHEMBL6108042 | 0.78 | ALDH1A1 (0.58) | PTPN1PTPRCALDH1A1TSHRMAPK1 | |
| SCHEMBL28789807 | 0.78 | PTPN1 (0.52) | PTPN1PTPRCALDH1A1CETPTSHR | |
| SCHEMBL417167 | 0.78 | MMP8 (0.58) | PTPN1PTPRCALDH1A1KMT2ALMNA | |
| SCHEMBL10894512 | 0.78 | ELANE (0.41) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115006324-A | Nourishing and repairing lotion containing ceramide NP and preparation method thereof | 广东格烯生物科技股份有限公司 | 2022-09-06 | — | — | CN | disclosed |
| US-7030262-B2 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | ABBOTT LABORATORIES (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1546087-A1 | 3-AMINO-2-HRYDROXYALKANOIC ACIDS AND THEIR PRODRUGS | Abbott Laboratories (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040122098-A1 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | ABBVIE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004013085-A1 | 3-AMINO-2-HRYDROXYALKANOIC ACIDS AND THEIR PRODRUGS | ABBOTT LABORATORIES (US) | 2004-02-12 | — | — | WO | disclosed |
| EP-0590789-B9 | Excitatory amino acid receptor antagonists | LILLY CO ELI (US) | 2004-02-04 | — | — | EP | disclosed |
| EP-0590789-B1 | Excitatory amino acid receptor antagonists | LILLY CO ELI (US) | 2003-03-12 | — | — | EP | disclosed |
| US-6268507-B1 | USEFUL AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTION USEFUL AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY | 2001-07-31 | — | — | US | disclosed |
| EP-0878463-B1 | Excitatory amino acid receptor modulators | LILLY CO ELI (US) | 2000-12-20 | — | — | EP | disclosed |
| US-6160009-A | Excitatory amino acid receptor modulators | ELI LILLY AND COMPANY (US) | 2000-12-12 | — | — | US | disclosed |
| US-5284957-A | Substituted 1H- or 2H-tetrazoles | ELI LILLY AND COMPANY (US) | 1994-02-08 | — | — | US | disclosed |
| EP-0345997-A2 | Azetidinone intermediates for 1-carba (dethia) cephalosporins | ELI LILLY AND COMPANY (US) | 1989-12-13 | — | — | EP | disclosed |
| EP-0345998-A1 | Process and intermediates for beta-lactam antibiotics | ELI LILLY AND COMPANY (US) | 1989-12-13 | — | — | EP | disclosed |
| US-4885362-A | Azetidinone intermediates for 1-carba(dethia)caphalosporins | ELI LILLY AND COMPANY (US) | 1989-12-05 | — | — | US | disclosed |
| US-4599330-A | 24,24-DIFLUORO-1,25-DIHYDROXYCHOLECALCIFEROL | HOFFMANN-LA ROCHE INC. (US) | 1986-07-08 | — | — | US | disclosed |
| EP-0063489-B1 | 4\"-MODIFIED METHYLENE OLEANDOMYCINS | PFIZER INC. (US) | 1984-06-27 | — | — | EP | disclosed |
| US-4421690-A | ANTI-RACHITOGENIC | HOFFMANN-LA ROCHE INC. (US) | 1983-12-20 | — | — | US | disclosed |
| US-4397847-A | OF OSTEOPOROSIS WITH 24,24-DIFLUORO-1,25-DIHYDROXYCHOLECALCIFEROL | HOFFMANN-LA ROCHE INC. (US) | 1983-08-09 | — | — | US | disclosed |
| EP-0063489-A1 | 4\"-Modified methylene oleandomycins | PFIZER INC. (US) | 1982-10-27 | — | — | EP | disclosed |
| US-4336368-A | 4 Deoxy-4-methylene oleandomycin and derivatives thereof | PFIZER INC. (US) | 1982-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122098-A1 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | HDGF, HCAR2, HCAR3 | PTPN1 2633/4885PTPRC 3204/4885ALDH1A1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.